Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2020): Barbieri MA+, J Clin Med 9(4), E122716%
Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
Adverse reactions attributed to entire drug class 'Biologic disease-modifying antirheumatic drug (bDMARD)'
Please login to view adverse reactions.
Lymphocytosis / lymphocytes increased
- (2020): Barbieri MA+, J Clin Med 9(4), E12279% (serious)
Neutropenia (neutrophils decreased)
- (2020): Barbieri MA+, J Clin Med 9(4), E122713% (serious)
Musculoskeletal adverse effects
- (2020): Barbieri MA+, J Clin Med 9(4), E122718%
Uveitis / anterior uveitis / posterior uveitis / panuveitis
- (2020): Barbieri MA+, J Clin Med 9(4), E12277% (serious)
Adverse effects / adverse reactions
- (2024): Skaarup L+, Drug Saf Jul, Online ahead of print [REVIEW]
- (2021): Martínez-Múgica C+, Farm Hosp 46(1), 15-20
- (2020): Cometi L+, J Clin Med 9(5), E1310
- (2020): Martínez-López-de-Castro N+, Eur J Rheumatol 7(2), 53-59
- (2020): Barbieri MA+, J Clin Med 9(4), E122722%
Click on the DRUG REVIEW ARTICLE link (above) to see a review of disease-modifying antirheumatic drugs in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
